Asia Pacific survey of physicians on asthma and allergic rhinitis (ASPAIR): data from China

作     者：David Hinds Bhumika Aggarwal Xin Du Aruni Mulgirigama Sumitra Shantakumar Hinds David;Aggarwal Bhumika;Du Xin;Mulgirigama Aruni;Shantakumar Sumitra

作者机构：Real World Evidence & Epidemiology GSK Collegeville PA 19426-0989 USA Respiratory Global Classic & Established Products GSK 139234 Singapore Respiratory Therapeutic area GSK Shanghai 201203 China Respiratory Franchise GSK Brentford Middlesex TW8 9GS UK Real World Evidence and Epidemiology GSK 139234 Singapore 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2019年第132卷第11期

页      面：1264-1271页

核心收录：

学科分类：1002[医学-临床医学] 10[医学] 

基　　金：supported by a grant from GlaxoSmithKline 

主　　题：Asthma Allergic rhinitis Coexistent asthma-allergic rhinitis China Asia-Pacific Survey of Physicians on Asthma and Allergic Rhinitis ASPAIR 

摘      要：Background:In China, the prevalence of allergic rhinitis (AR) and asthma has increased in the past decade. As these two diseases frequently coexist, the Asia-Pacific Survey of Physicians on Asthma and Allergic Rhinitis (ASPAIR) study aimed to assess physicians5 beliefs and treatment patterns of coexistent asthma-AR across six Asian countries. This analysis presents the results from China. Methods: The 200 hospital-based general physicians and pediatricians were interviewed from five cities in China. Physicians were questioned in-person about their knowledge, beliefs and management practices for patients with coexistent asthma-AR. Results: Approximately 70% of the physicians interviewed routinely evaluated their patients with asthma or AR for signs of coexistent disease. While the majority of physicians (90% of physicians) recognized the increased burden of coexistent asthma-AR vs. one condition alone and that coexistent disease requires additional treatment, most physicians (96%) also believed that patients with coexistent asthma-AR were well managed if either condition alone improved. Similarly, although 71% of physicians selected a combination of intranasal and inhaled corticosteroids as their preferred treatment for coexistent asthma-AR, in line with treatment guidelines, two fifths of physicians indicated that treatment for coexistent disease requires too much medication and that their patients prefer oral medications and a third of physicians believed that corticosteroids should be delayed in children. Conclusions: This survey demonstrates that physicians interviewed in China have a broad understanding of coexistent asthma-AR and its impact on patients. A holistic approach to patient management with informed decisions regarding patients overall treatment will benefit patients who suffer from coexistent disease.